Onkologie. 2021:15(1):35-39 [Urol. praxi. 2020;21(4):156-159]

Treatment of non-metastatic castration-resistant prostate cancer

Ivo Kocák
Masarykův onkologický ústav a LF MU Brno

Men with non-metastatic castration-resistant prostate cancer with short doubling time PSA are at risk for early disease progression. Results of new clinical studies with antiandrogens II. generations such as apalutamide, enzalutamide, darolutamide have been shown to delay the onset of metastatic disease and prolong survival in these patients.

Keywords: hormone-sensitive diseases, castration resistance, prostate antigen (PSA), non-metastatic castration-resistant prostate cancer, apalutamide, enzalutamide, darolutamide.

Published: March 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kocák I. Treatment of non-metastatic castration-resistant prostate cancer. Onkologie. 2021;15(1):35-39.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mottet N, Cornford P, van den Bergh RCN, Briers E. Prostate Cancer guidelines. EAU Guidelines Edn presented at the EAU Annual Congress Amsterdam 2020: EAU Guidelines Office, Arnhem, The Netherlands 2020.
    2. Kolektiv autorů. Modrá kniha České onkologické společnosti. Masarykův onkologický ústav; 2020.
    3. Scher HI, et al. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2020; 26: 1148-1159. Go to original source... Go to PubMed...
    4. Tombal B. Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? [in eng]. Ann Oncol 2012; 23(Suppl 10(suppl 22987972) Sep: x251-258. Go to original source... Go to PubMed...
    5. Smith MR, Saad F, Oudard S, et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013; 31: 3800-3806. Go to original source... Go to PubMed...
    6. Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer [in eng]. N Engl J Med 2018; 378(15)(Suppl. 29420164) Apr: 1408-1418. Go to original source... Go to PubMed...
    7. Smith MR, et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol (2020), https://doi.org/10.1016/j.eururo.2020.08.011. Go to original source... Go to PubMed...
    8. Small EJ, Saad F, Chowdhury S, et al. Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO 2020; Virtual. J Clin Oncol 2020; 38(Suppl; abstr 5516). Go to original source...
    9. Hussain M, Fizazi K, Saad F, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer [in eng]. N Engl J Med. 2018; 378(26) (Suppl. 29949494) Jun: 2465-2474. Go to original source... Go to PubMed...
    10. Sternberg CN, et al. Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology 2020; 38(Suppl. 15): 5515-5515. Go to original source...
    11. Fizazi K, Shore N, Tammela TL, et al. Darolutamide in Nonmetastatic, Castration- Resistant Prostate Cancer [in eng]. N Engl J Med. 2019; 380(13)(suppl 30763142) 03: 1235-1246. Go to original source... Go to PubMed...
    12. Fizazi K, et al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med 2020; 383: 1040-1049. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.